Abstract: An object of the present invention is to provide a pharmaceutical composition, in particular, a compound suitable for preventing and/or treating inflammatory diseases and/or neurodegenerative disease. The present inventors have conducted intensive studies to find a compound having an inhibitory effect on NLRP3 inflammasome activation and found that an annulated pyridazine compound has an inhibitory effect on NLRP3 inflammasome activation, thus completing the present invention. The annulated pyridazine compound of the present invention is expected to serve as a prophylactic and/or therapeutic agent for inflammatory diseases and/or neurodegenerative diseases.

Abstract: One drug (preparation) of the present invention is a drug for a reproductive disorder containing a silicon fine particle, an aggregate of silicon fine particles or a crystal grain of silicon having a hydrogen-generating ability. Hydrogen generated from the silicon fine particle in the drug can contribute to the prevention and/or treatment of reproductive disorder.

Abstract: An object of the present invention is to provide a pharmaceutical composition, particularly a compound suitable for preventing and/or treating an inflammatory disease and/or a neurodegenerative disease. The present inventors accomplished the present invention by conducting intensive studies to find a compound having an inhibitory effect on NLRP3 inflammasome activation, with the result that a substituted triazine compound is found to have the inhibitory effect on NLRP3 inflammasome activation. The substituted triazine compound of the present invention is expected to serve as a preventive and/or therapeutic drug for an inflammatory disease and/or a neurodegenerative disease.

Abstract: The purpose of the present invention is to provide a flight control mechanism for controlling flight of an unmanned aerial vehicle by controlling collision between the vehicle and a boundary surface, an unmanned aerial vehicle equipped with the mechanism, and a method for using the mechanism and the vehicle. Provided is a flight control mechanism for an unmanned aerial vehicle including: a first initial collision member; a second initial collision member; and a holding member that holds the first and second initial collision members with a space therebetween above the body of the unmanned aerial vehicle, is tiltable with respect to the vehicle body by rotating about a predetermined position inside or above the vehicle body toward the side of the vehicle body, and rotates in response to collision between the first or second initial collision member and a boundary surface.

Abstract: Provided is an unmanned aircraft which is capable of stably taking off. In one example, the unmanned aircraft has an aircraft body which includes an information acquisition device, a plurality of rotary wings, and a protective member disposed around the rotary wings. Each of the rotary wings has a rotation axis which is tilted with respect to a vertical direction by a given angle, such that the rotary wings generate a forward thrust force. The aircraft body has a lower edge which includes a middle lower edge and a forward lower edge, wherein the protective member has a lower edge including the forward lower edge. The forward lower edge is located above the middle lower edge, and the forward lower edge has a rear end located backward of a rear end of the rotary wing.

Abstract: Provided is an unmanned aircraft which is capable of stably taking off. In one example, the unmanned aircraft has an aircraft body which includes an information acquisition device, a plurality of rotary wings, and a protective member disposed around the rotary wings. Each of the rotary wings has a rotation axis which is tilted with respect to a vertical direction by a given angle, such that the rotary wings generate a forward thrust force. The aircraft body has a lower edge which includes a middle lower edge and a forward lower edge, wherein the protective member has a lower edge including the forward lower edge. The forward lower edge is located above the middle lower edge, and the forward lower edge has a rear end located backward of a rear end of the rotary wing.

Abstract: The present invention addresses the problem of providing a pharmaceutical composition, in particular a compound suitable for prevention and/or treatment of an inflammatory disease and/or a neurodegenerative disease. The inventors of the present invention conducted extensive studies to find a compound that has suppressive action on NLRP3 inflammasome activation, and found that a substituted pyridazine compound has suppressive action on NLRP3 inflammasome activation, leading to completion of the present invention. The substituted pyridazine compound according to the present invention is expected to serve as a drug for prevention and/or treatment of an inflammatory disease and/or a neurodegenerative disease.

Abstract: Provided are a device configuration, method, etc. for performing imaging investigation in an investigation space using an unmanned aerial vehicle. A system includes: a flight start platform; the vehicle which is connected to a line-type member and equipped with an investigation camera, a travel-direction imaging camera, and a vehicle-side communication unit; an external control device which is equipped with a display unit and an external control device-side communication unit, and which receives the travel-direction image data through the external control device-side communication unit, receives an input of control commands for the vehicle while having a video or still image obtained from the travel-direction image data displayed on the display unit, and transmits a signal indicating the control commands from the external control device-side communication unit; and an attraction device which is connected to the line-type member and attracts the vehicle.

Abstract: One drug (preparation) of the present invention is a drug for a reproductive disorder containing a silicon fine particle, an aggregate of silicon fine particles or a crystal grain of silicon having a hydrogen-generating ability. Hydrogen generated from the silicon fine particle in the drug can contribute to the prevention and/or treatment of reproductive disorder.

Abstract: The purpose of the present invention is to provide a moving object comprising a configuration suitable for miniaturization in a view from at least one direction, and to provide a method for using the same. Provided is a moving object comprising: two or more rotors positioned at the front side and at the rear side in the traveling direction; and a driving device that drives the two or more rotors and rotates at least two of the two or more rotors in mutually different directions.

Abstract: The objective of the present invention is to provide a device configuration, a method and the like for performing an imaging survey within a survey space using an unmanned aerial vehicle. Provided is an unmanned aerial vehicle provided with at least four rotating blades, and a control unit which controls the rotation of the at least four rotating blades, wherein the unmanned aerial vehicle is provided with a survey camera in a position on a chassis of the unmanned aerial vehicle, between at least one rotating blade positioned on the side in the direction of travel, from among the at least four rotating blades, and at least one rotating blade positioned on the opposite side to the direction of travel, and wherein, when flying above a surface in which a liquid is at least partially present, the unmanned aerial vehicle flies while at least partially preventing scattered liquid from reaching above the chassis by means of the at least four rotating blades.

Abstract: Provided are a device configuration, method, etc. for performing imaging investigation in an investigation space using an unmanned aerial vehicle. A system includes: a flight start platform; the vehicle which is connected to a line-type member and equipped with an investigation camera, a travel-direction imaging camera, and a vehicle-side communication unit; an external control device which is equipped with a display unit and an external control device-side communication unit, and which receives the travel-direction image data through the external control device-side communication unit, receives an input of control commands for the vehicle while having a video or still image obtained from the travel-direction image data displayed on the display unit, and transmits a signal indicating the control commands from the external control device-side communication unit; and an attraction device which is connected to the line-type member and attracts the vehicle.

Abstract: The purpose of the present invention is to provide a flight control mechanism for controlling flight of an unmanned aerial vehicle by controlling collision between the vehicle and a boundary surface, an unmanned aerial vehicle equipped with the mechanism, and a method for using the mechanism and the vehicle. Provided is a flight control mechanism for an unmanned aerial vehicle including: a first initial collision member; a second initial collision member; and a holding member that holds the first and second initial collision members with a space therebetween above the body of the unmanned aerial vehicle, is tiltable with respect to the vehicle body by rotating about a predetermined position inside or above the vehicle body toward the side of the vehicle body, and rotates in response to collision between the first or second initial collision member and a boundary surface.

Abstract: The problem to be solved by the present invention is to provide a compound suitable for a pharmaceutical composition, specifically a pharmaceutically composition for treating nocturia. The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, would maintain and/or increase an endogenous AVP level to enhance the antidiuretic effect, which would contribute to a decreased number of nocturnal voids, and have extensively studied compounds which inhibit P-LAP. As a result, the inventors have found that (2R)-3-amino-2-{[4-(substituted pyridine)-2-yl]methyl}-2-hydroxy-propanoic acid derivatives have excellent P-LAP inhibitory activity. The inventors have evaluated antidiuretic effects in water-loaded rats and have found that the compounds increase endogenous AVP levels by inhibiting P-LAP and consequently reduce urine production.

Abstract: The problem to be solved by the present invention is to provide a compound suitable for a pharmaceutical composition, specifically a pharmaceutically composition for treating nocturia. The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, would maintain and/or increase an endogenous AVP level to enhance the antidiuretic effect, which would contribute to a decreased number of nocturnal voids, and have extensively studied compounds which inhibit P-LAP. As a result, the inventors have found that (2R)-3-amino-2-{[4-(substituted pyridine)-2-yl]methyl}-2-hydroxy-propanoic acid derivatives have excellent P-LAP inhibitory activity. The inventors have evaluated antidiuretic effects in water-loaded rats and have found that the compounds increase endogenous AVP levels by inhibiting P-LAP and consequently reduce urine production.

Abstract: The purpose of the present invention is to provide a highly efficient method for capturing images inside a confined space without the need for direct visual observation by an inspector. Provided is an unmanned aerial vehicle equipped with at least four rotors, a drive device that drives the rotors, a control signal generation circuit that generates a control signal for causing the drive device to drive the rotors, and an imaging camera, wherein said unmanned aerial vehicle is configured to fly within a confined space by driving the rotors while capturing images inside the confined space by means of the imaging camera.

Abstract: The problem to be solved by the present invention is to provide a compound suitable for a pharmaceutical composition, specifically a pharmaceutically composition for treating nocturia. The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, would maintain and/or increase an endogenous AVP level to enhance the antidiuretic effect, which would contribute to a decreased number of nocturnal voids, and have extensively studied compounds which inhibit P-LAP. As a result, the inventors have found that (2R)-3-amino-2-{[4-(substituted pyridine)-2-yl]methyl}-2-hydroxy-propanoic acid derivatives have excellent P-LAP inhibitory activity. The inventors have evaluated antidiuretic effects in water-loaded rats and have found that the compounds increase endogenous AVP levels by inhibiting P-LAP and consequently reduce urine production.

Abstract: The problem to be solved by the present invention is to provide a compound suitable for a pharmaceutical composition, specifically a pharmaceutically composition for treating nocturia. The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, would maintain and/or increase an endogenous AVP level to enhance the antidiuretic effect, which would contribute to a decreased number of nocturnal voids, and have extensively studied compounds which inhibit P-LAP. As a result, the inventors have found that (2R)-3-amino-2-{[4-(substituted pyridine)-2-yl]methyl}-2-hydroxy-propanoic acid derivatives have excellent P-LAP inhibitory activity. The inventors have evaluated antidiuretic effects in water-loaded rats and have found that the compounds increase endogenous AVP levels by inhibiting P-LAP and consequently reduce urine production.

Abstract: The problem to be solved by the present invention is to provide a compound suitable for a pharmaceutical composition, specifically a pharmaceutically composition for treating nocturia. The inventors have assumed that inhibition of nocturnal activity of placental leucine aminopeptidase (P-LAP), i.e. aminopeptidase that cleaves AVP, would maintain and/or increase an endogenous AVP level to enhance the antidiuretic effect, which would contribute to a decreased number of nocturnal voids, and have extensively studied compounds which inhibit P-LAP. As a result, the inventors have found that (2R)-3-amino-2-{[4-(substituted pyridine)-2-yl]methyl}-2-hydroxy-propanoic acid derivatives have excellent P-LAP inhibitory activity. The inventors have evaluated antidiuretic effects in water-loaded rats and have found that the compounds increase endogenous AVP levels by inhibiting P-LAP and consequently reduce urine production.